Axonics Modulation Technologies Inc Total Assets
Axonics Modulation Technologies Inc total assets. Based on the latest financial reports, Axonics Modulation Technologies Inc (AXNX) holds total assets worth $774.17 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AXNX cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Axonics Modulation Technologies Inc (2016–2023)
Total assets of Axonics Modulation Technologies Inc from 2016 to 2023. This chart illustrates how Axonics Modulation Technologies Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Axonics Modulation Technologies Inc for real-time trading data and today's change.
Axonics Modulation Technologies Inc - Asset Composition Analysis
Axonics Modulation Technologies Inc Total Assets Breakdown (December 2023)
Axonics Modulation Technologies Inc total assets breakdown as of December 2023. Axonics Modulation Technologies Inc's total assets of $774.17 Million consist of 68.3% current assets and 31.7% non-current assets. Explore AXNX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.6% |
| Accounts Receivable | $57.24 Million | 8.0% |
| Inventory | $79.94 Million | 11.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $81.38 Million | 11.3% |
| Goodwill | $99.42 Million | 13.8% |
Asset Composition Trend (2016–2023)
This chart illustrates how Axonics Modulation Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axonics Modulation Technologies Inc's current assets represent 68.3% of total assets in 2023, a decrease from 80.4% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2023, down from 75.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 6.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 13.8% of total assets.
Axonics Modulation Technologies Inc Competitors by Total Assets
Key competitors of Axonics Modulation Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$9.96 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
Israel | ILA37.04 Million |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$95.27 Million |
|
ViroGates A/S
CO:VIRO
|
Denmark | Dkr26.77 Million |
|
Spineguard
PA:ALSGD
|
France | €8.35 Million |
Axonics Modulation Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.16 | 13.36 | 17.59 |
| Quick Ratio | 6.40 | 11.25 | 16.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $461.50 Million | $439.79 Million | $199.65 Million |
Axonics Modulation Technologies Inc - Advanced Valuation Insights
This section examines the relationship between Axonics Modulation Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.46 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 9.2% |
| Total Assets | $719.92 Million |
| Market Capitalization | $40.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Axonics Modulation Technologies Inc's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Axonics Modulation Technologies Inc's assets grew by 9.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Axonics Modulation Technologies Inc (2016–2023)
The table below shows the annual total assets of Axonics Modulation Technologies Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $719.92 Million | +9.19% |
| 2022-12-31 | $659.35 Million | +20.33% |
| 2021-12-31 | $547.95 Million | +60.12% |
| 2020-12-31 | $342.21 Million | +55.67% |
| 2019-12-31 | $219.82 Million | +27.87% |
| 2018-12-31 | $171.91 Million | +484.48% |
| 2017-12-31 | $29.41 Million | +170.93% |
| 2016-12-31 | $10.86 Million | -- |
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more